^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MV-NIS

    i
    Other names: MV-NIS, MVNIS, MV NIS, sodium iodide simporter measles virus
    Associations

    News

    Trials
    Company:
    Vyriad
    Drug class:
    Immunostimulant, Cell death stimulant
    Related drugs:
    Associations

    News

    Trials
    5ms
    MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov)
    P1/2, N=57, Recruiting, Mayo Clinic | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    MV-NIS
    8ms
    Oncolytic virotherapies for pediatric tumors. (PubMed, Expert Opin Biol Ther)
    We reviewed seven virus types that have been investigated in past or ongoing pediatric tumor clinical trials: adenovirus (AdV-tk, Celyvir, DNX-2401, VCN-01, Ad-TD-nsIL-12), herpes simplex virus (G207, HSV-1716), vaccinia (JX-594), reovirus (pelareorep), poliovirus (PVSRIPO), measles virus (MV-NIS), and Senecavirus A (SVV-001). However, the antitumor effects of OVT remain variable depending on tumor type and viral agent used. Although the widespread adoption of OVT faces many challenges, we are optimistic that OVT will play an important role alongside standard chemotherapy and radiotherapy for the treatment of malignant pediatric solid tumors in the future.
    Review • Journal • Oncolytic virus
    |
    ProstAtak (aglatimagene besadenovec) • Reolysin (pelareorep) • tasadenoturev (DNX-2401) • HSV G207 • MV-NIS • Pexa-Vec (pexastimogene devacirepvec) • SVV-001 • Seprehvir (HSV1716) • VCN-01
    11ms
    MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov)
    P1/2, N=57, Recruiting, Mayo Clinic | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
    |
    MV-NIS
    11ms
    Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy (clinicaltrials.gov)
    P1, N=8, Completed, Vyriad, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • MV-NIS
    12ms
    Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT (clinicaltrials.gov)
    P1, N=34, Completed, Sabine Mueller, MD, PhD | Recruiting --> Completed | Trial completion date: May 2024 --> May 2023 | Trial primary completion date: Dec 2023 --> May 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    MV-NIS
    1year
    Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, Vyriad, Inc. | Recruiting --> Active, not recruiting | N=16 --> 8 | Trial completion date: Dec 2022 --> May 2023 | Trial primary completion date: Apr 2022 --> May 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    cisplatin • MV-NIS
    1year
    Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=12, Completed, Mayo Clinic | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive
    |
    MV-NIS
    almost2years
    Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT (clinicaltrials.gov)
    P1, N=46, Recruiting, Sabine Mueller, MD, PhD | Trial completion date: May 2023 --> May 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    MV-NIS
    2years
    Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT (clinicaltrials.gov)
    P1, N=46, Recruiting, Sabine Mueller, MD, PhD | Trial completion date: Nov 2022 --> May 2023 | Trial primary completion date: Jun 2022 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    MV-NIS
    2years
    MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov)
    P1/2, N=57, Recruiting, Mayo Clinic | Trial completion date: Mar 2022 --> Dec 2023 | Trial primary completion date: Mar 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
    |
    MV-NIS
    over2years
    Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2021 --> Dec 2022
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive
    |
    MV-NIS
    over2years
    The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma. (PubMed, Cancers (Basel))
    Current anti-myeloma therapies (conventional chemotherapies, immunomodulatory drugs i.e., thalidomide and its' analogues, proteasome inhibitors, monoclonal antibodies, and radiotherapy) initially substantially debulk tumour burden, but after a period of remission 'plateau phase' disease invariably relapses due to tumour recrudescence from foci of minimal residual disease (MRD) and accumulating drug resistance...This review will discuss the potential use of oncolytic virus (OV) therapies in the treatment of myeloma. Specifically, it will focus on preclinical studies using DNA viruses (adenovirus (Ad), vaccinia virus (VV), myxoma virus (MYXV), and herpes simplex virus (HSV)), RNA viruses (reovirus (reo), coxsackie virus, measles virus (MV) and bovine viral diarrhoea virus (BVDV), and vesicular stomatitis virus (VSV)), and on four types of viruses (VV, reo, MV-NIS and VSV-IFNβ-NIS) that have been assessed clinically in a small number of myeloma patients.
    Review • Journal • Oncolytic virus
    |
    IFNB1 (Interferon Beta 1)
    |
    thalidomide • MV-NIS • Voyager-V1
    almost3years
    Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT (clinicaltrials.gov)
    P1, N=46, Recruiting, Sabine Mueller, MD, PhD | Trial primary completion date: Nov 2021 --> Jun 2022
    Clinical • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    MV-NIS
    3years
    MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov)
    P1/2, N=57, Recruiting, Mayo Clinic | Trial completion date: Jun 2021 --> Mar 2022 | Trial primary completion date: Jun 2021 --> Mar 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
    |
    MV-NIS
    3years
    Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2020 --> Dec 2021
    Clinical • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive
    |
    MV-NIS
    4years
    Phase I/II Trial of Adipose Tissue Derived Mesenchymal Stem Cell Delivery of a Measles Virus Strain Engineered to Express the Sodium Iodide Symporter in Ovarian Cancer Patients (ASGCT 2020)
    We conducted first in human trials of intraperitoneal (IP) administration of the MV-CEA (expressing the human carcinoembryonic antigen) and MV-NIS strains and we demonstrated excellent safety and evidence of biologic activity as indicated by decreases in tumor marker CA125, and promising median overall survival of 26.6 mo (vs expected survival of only 6-12 mos) in a heavily pretreated patient population (Galanis et al, Cancer Res)... Adipose tissue derived MSC can safely deliver MV strains without dose limiting toxicity being encountered. This form of cell based delivery resulted in cell dose dependent improvement in clinical outcome and development of antitumor cellular and humoral immune responses. A phase II trial of this approach is ongoing with 9 pts having enrolled todate; updated data will be presented at the meeting.
    Clinical • P1/2 data
    |
    HER-2 (Human epidermal growth factor receptor 2) • IFNG (Interferon, gamma) • IGFBP2 (Insulin-like growth factor binding protein 2) • IL17A (Interleukin 17A)
    |
    MV-NIS
    over4years
    Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2019 --> Dec 2020
    Clinical • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive
    |
    MV-NIS